60 Degrees Pharmaceuticals Inc (SXTP)

Feb 21, 2025, 9:00 AM EST - 5 weeks ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

Feb 20, 2025, 10:36 AM EST - 6 weeks ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 11, 2025, 12:59 PM EST - 7 weeks ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 6, 2025, 2:07 PM EST - 2 months ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 2 months ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 2 months ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 28, 2025, 8:01 AM EST - 2 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 8, 2025, 8:02 AM EST - 3 months ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Dec 23, 2024, 8:57 AM EST - 3 months ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 11, 2024, 8:56 AM EST - 4 months ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 2, 2024, 4:05 PM EST - 4 months ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

Nov 22, 2024, 9:00 AM EST - 4 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

Nov 14, 2024, 2:31 PM EST - 5 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Oct 3, 2024, 9:02 AM EDT - 6 months ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Sep 12, 2024, 7:19 AM EDT - 7 months ago

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

HYLN COCH

Sep 4, 2024, 8:00 AM EDT - 7 months ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Aug 28, 2024, 2:48 PM EDT - 7 months ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2024, 11:01 AM EDT - 8 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 12, 2024, 9:12 AM EDT - 8 months ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 6, 2024, 9:26 AM EDT - 8 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Jul 25, 2024, 9:02 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 19, 2024, 8:29 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 9, 2024, 6:31 AM EDT - 9 months ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Jun 27, 2024, 7:59 AM EDT - 10 months ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

May 30, 2024, 7:59 AM EDT - 11 months ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

May 20, 2024, 7:59 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 15, 2024, 1:45 PM EDT - 11 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

May 8, 2024, 7:59 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

May 2, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Apr 3, 2024, 7:58 AM EDT - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

Mar 14, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

Feb 20, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Feb 8, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Jan 31, 2024, 12:00 PM EST - 1 year ago

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 31, 2024, 11:15 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

Jan 30, 2024, 9:45 AM EST - 1 year ago

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 30, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Jan 22, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Jan 16, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

Dec 26, 2023, 7:59 AM EST - 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

Nov 15, 2023, 7:29 AM EST - 1 year ago

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

Oct 19, 2023, 8:31 AM EDT - 1 year ago

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

Oct 12, 2023, 4:16 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

Sep 18, 2023, 4:16 PM EDT - 1 year ago

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Sep 6, 2023, 7:31 AM EDT - 1 year ago

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Sep 1, 2023, 9:00 AM EDT - 1 year ago

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

GENE

Aug 30, 2023, 7:32 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Aug 22, 2023, 7:31 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

Aug 15, 2023, 7:31 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

Jul 31, 2023, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects